People with type 1 diabetes show reduced or absent expression of several key defensin antimicrobial peptides in their pancreas, regardless of inflammation level, suggesting innate immune dysfunction.
Defensins absentregardless of inflammation level in type 1 diabetes pancreas
What the researchers found
Type 1 diabetes patients showed reduced or absent expression of defensins Beta-1, Alpha-1, Cathelicidin, and REG3A in the pancreas, decoupled from inflammation levels, unlike normal controls.
Why it matters
This is one of the first studies to characterize the defensin system in the diabetic pancreas, revealing a potential innate immune dysfunction that could contribute to disease pathogenesis and may open new therapeutic avenues.
The numbers in context
Studied pancreases from non-diabetic donors of different ages and from subjects with different stages of type 1 diabetes.
How the study worked
Immunohistochemical analysis of eight different defensins and immune cell markers (CD3+, CD45+, CD68+, NES+) across head, body, and tail sections of pancreases from non-diabetic donors of various ages and type 1 diabetes donors with varying disease duration.
Who was studied
Pancreatic biopsies from type 1 diabetes patients and non-diabetic donors
What this study cannot tell us
Small sample sizes typical of human pancreas studies (organ donor tissue is scarce); observational without mechanistic experiments to determine causality; unclear whether defensin loss is cause or consequence of the disease process.
How to read the evidence
Preliminary evidence from human pancreatic tissue analysis. Novel finding with important implications, but small sample sizes and observational design limit conclusions about causality.
When this study was published
Published in 2024, representing emerging research into innate immunity's role in type 1 diabetes.
The bigger picture
Type 1 diabetes is primarily understood as an autoimmune (adaptive immunity) disease, but this study suggests the innate immune system — specifically antimicrobial peptide production — is also fundamentally disrupted, potentially contributing to the disease process.
Questions still open
- Does defensin loss in the pancreas precede or follow the autoimmune attack in type 1 diabetes?
- Could restoring pancreatic defensin levels slow disease progression?
- Is the defensin dysfunction specific to the pancreas or present systemically in type 1 diabetes?
Common questions
What are defensins and why do they matter in diabetes?
Could this finding lead to new treatments for type 1 diabetes?
Read the original research
Reduced expression of central innate defense molecules in pancreatic biopsies from subjects with Type 1 diabetes.
Acta diabetologica, 61(9), 1117-1127
Citation
Tegehall, Angie; Ingvast, Sofie; Krogvold, Lars; Dahl-Jørgensen, Knut; Korsgren, Olle. (2024). Reduced expression of central innate defense molecules in pancreatic biopsies from subjects with Type 1 diabetes.. Acta diabetologica, 61(9), 1117-1127. https://doi.org/10.1007/s00592-024-02286-1